About Us

International Clinical Trials specialise in finding safer drugs for patients who drive motor vehicles.

Unique market research methodologies have been developed that quantifies the percentage of current patients immediately changed to a minimally sedating drug as well as the percentage of new patients initiated on the low sedating agent.

These highly sensitive methodologies that apply to every drug class are licensed out to pharmaceutical companies that possess drugs of low sedation.

Clinical trial protocols have been specifically developed to differentiate between antipsychotics that impair driving from those that do not adversely impact on driver safety.

Licensing of know-how and trade secrets of these clinical trial methodologies result in a label addition that establishes superior safety over sedating medications.

This ensures a rapid transfer of patients from sedating drugs to those that do not impact driver safety obtaining maximum commercialization of low sedating compounds.



THE PROBLEM

1.35 MILLION ROAD DEATHS ANNUALLY WORLDWIDE

  • Road traffic injuries are the leading cause of death for the 15-29-year age group and the second most common cause of death for those aged 5-14 years.

  • 43% of deceased US road traffic accident victims had drugs and 37% had alcohol found in their bloodstream.

  • 80 diseases and 35 therapeutic drug classes significantly impair driver safety.

  • Drug interactions with sedating drugs and impaired reaction times on ageing contribute to the high mortality of drivers.

  • 33% of patients suffering from schizophrenia and schizoaffective disorders are involved in car accidents.


MISSION


VISION


Constantly strive to find medications that are
safer for patients who drive cars.
Continuous worldwide annual reduction in
deaths, serious injury and property damage
caused by motor vehicle accidents.


BUSINESS MODEL

International Clinical Trials business model is based on partnerships with other pharmaceutical companies that possess minimally sedating medications.

Commercial returns for low sedating drugs are maximised throughout their product life cycle by early clinical trial comparisons with heavily sedating agents.



BUSINESS FOUNDER

Val Schabinsky is an author, media expert consultant who has studied the effects of drugs on driving vehicles for 44 years.

His book, Diseases Impairing Driving: Strategies for Accident Prevention debut at number 1 for driver’s education on Amazon Kindle on 18 August 2019.

He founded International Clinical Trials in January 2005 and has served as director and chairman since incorporation occurred on 24 October 2011.

Previously he worked in various roles in the pharmaceutical industry at Bristol-Myers Squibb & Merck.

He also pioneered the positions of medical product specialist at Janssen-Cilag & medical communications manager at Pfizer.

Before this, he was the first person in the world to research the mechanism of acute tolerance to alcohol and obtained four years of academic teaching experience in the Department of Pharmacology, The University of Sydney.

Val holds a Bachelor of Science and a Master of Science degree in Pharmacology from The University of Sydney.



Contact Us

Contact us to ensure that our unique research methodologies save lives by reducing motor vehicle accidents and ensure maximum commercialization of your drug.





CONTACT US

Email Us Follow on Twitter

Val Schabinsky

Founder and Chairman

37 President Road Kellyville
NSW Australia 2155

Tel: +61298361669
Mob: +61404876694
Fax: +61298361669
Web: www.internationalclinicaltrials.com


diseases impairing driving